A study explored patients with multiple relapsed or refractory multiple myeloma (MM) and their need for innovative treatments due to shorter survival rates. Researchers suggest comprehensive restaging, including imaging and bone marrow biopsies, as essential for these patients. New therapies, like CAR T-cell and bispecific antibody therapy, are proving effective for relapsed/refractory MM, while the emergence of CAR T-cell therapy, especially BCMA-directed therapies and bispecific antibodies, offers promising new treatment avenues for patients with relapsed/refractory myeloma.

Reference: Catamero D, Richards T, Faiman B. A Focus on CAR T-Cell Therapy and Bispecific Antibodies in Multiple Myeloma. J Adv Pract Oncol. 2022 Jul;13(Suppl 4):31-43. doi: 10.6004/jadpro.2022.13.5.13. Epub 2022 Jul 28. PMID: 35937467; PMCID: PMC9342926. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9342926/